EP2736542A1 - Pansement multicouche contenant un hydrocolloïde et du charbon actif - Google Patents

Pansement multicouche contenant un hydrocolloïde et du charbon actif

Info

Publication number
EP2736542A1
EP2736542A1 EP12756104.1A EP12756104A EP2736542A1 EP 2736542 A1 EP2736542 A1 EP 2736542A1 EP 12756104 A EP12756104 A EP 12756104A EP 2736542 A1 EP2736542 A1 EP 2736542A1
Authority
EP
European Patent Office
Prior art keywords
activated carbon
wound dressing
wound
hydrocolloid
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12756104.1A
Other languages
German (de)
English (en)
Other versions
EP2736542B1 (fr
Inventor
Hasso von Blücher
Raik SCHÖNFELD
Frank Pallaske
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bluecher GmbH
Original Assignee
Bluecher GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bluecher GmbH filed Critical Bluecher GmbH
Priority to PL12756104T priority Critical patent/PL2736542T3/pl
Publication of EP2736542A1 publication Critical patent/EP2736542A1/fr
Application granted granted Critical
Publication of EP2736542B1 publication Critical patent/EP2736542B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/00051—Accessories for dressings
    • A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F13/15—Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/28—Polysaccharides or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
    • A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
    • A61L15/325—Collagen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/425—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/60—Liquid-swellable gel-forming materials, e.g. super-absorbents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00544—Plasters form or structure
    • A61F2013/00604—Multilayer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00655—Plasters adhesive
    • A61F2013/00676—Plasters adhesive hydrogel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/0091—Plasters containing means with disinfecting or anaesthetics means, e.g. anti-mycrobic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A61F2013/00361—Plasters
    • A61F2013/00902—Plasters containing means
    • A61F2013/00914—Plasters containing means with deodorising or perfuming means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
    • A61L2300/108—Elemental carbon, e.g. charcoal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents

Definitions

  • the present invention relates to the medical field of wound care or wound healing, in particular based on a local application of a wound dressing.
  • the present invention relates to a wound dressing, which is preferably suitable for the therapeutic wound care of the human or animal body.
  • the present invention relates to the use of the wound dressing of the invention for therapeutic wound care.
  • a wound is understood, in accordance with medical definition and in the context of the present invention, to mean an interruption of the relationship between body tissues with or without loss of substance, such interruption generally being caused by mechanical injuries or physically caused cell damage.
  • Wounds are classified into different types according to their trigger. For example, wounds created under the influence of external force are grouped under a mechanical wound, these being, above all, cut and puncture wounds, squeezing, locating, scratching and abrasions. Another form of wounds refers to thermal wounds caused by exposure to extreme heat or cold. In contrast, chemical wounds are brought about by the action of chemicals, in particular by chemical burns with acids or alkalis. As radiation-related wounds such tissue disruption or destruction are referred to, which under the influence of actinic radiation, eg. B. ultraviolet radiation, and / or ionizing radiation.
  • actinic radiation eg. B. ultraviolet radiation, and / or ionizing radiation.
  • Wound healing d. H.
  • the first phase - also referred to as latency or inflammation phase - within the first hours after injury has occurred, the exudation of body fluids, in particular of blood, to free the wound gap of foreign bodies, germs and dead tissue.
  • a scab is formed, which protects the wound to the outside against the ingress of germs and foreign bodies.
  • the sorptive phase of the latency phase begins, in which catabolic autolysis also takes place, ie macrophages migrate into the wound tissue and phagocytose the coagulated blood in the wound gap.
  • any foreign bodies or microorganisms that have penetrated are degraded in this phase, which may be associated with mild to moderate inflammatory symptoms.
  • the structure of the basal epithelium and granulation tissue begins.
  • the latency phase is generally completed, and the latency phase transitions to the second phase, the so-called proliferation or granulation phase, which generally continues from the fourth to the seventh day after the injury , This begins the anabolic repair, which in particular designates the formation of collagen by fibroblasts.
  • wound healing For further information on the concept of wound healing, reference may be made to Pschyrembel - Clinical Dictionary, 257th Edition, 1994, Verlag de Gruyer, Berlin / New York, page 1670, keyword “wound healing", the entire contents of which are hereby incorporated by reference is included.
  • a relatively common complication in wound healing represent wound infections caused by bacteria, fungi or viruses, which are particularly due to a lack of wound hygiene or the increased occurrence of germs, as is often the case in hospitals. Contamination with various microorganisms may result in particular bacterial infections of the wound, as a result of the infection classic signs of local inflammation occur, such as pain, swelling, redness and overheating. In the worst case, however, it may also come as a result of phlegmonösen - ie widespread - spread to a general infection or life-threatening sepsis with high fever and chills.
  • ka classes such as glycopeptide antibiotics, sulfonamides, quinolones or tetracyclines, have resistance.
  • infections with such germs must therefore be independent of the administration of antibiotics therapy to prevent systemic spread of the pathogen in the body.
  • there is still a serious deficiency in such therapy concepts in the prior art with the result that the death rate from multidrug-resistant hospital germs exceeds the mortality rate caused by seasonal influenza.
  • necrosis Another problem in wound healing can be the formation of necrosis, which leads to the pathological death of cells on the living organism.
  • successful therapy usually requires debridement, which refers to the excision of the dead tissue and serves to stimulate wound healing and prevent the spread of wound infection.
  • Debridement can be both surgically z. B. by scalpel and ring curette as well as enzymatically, autolytic or biosurgical.
  • such treatment is usually associated with severe pain for the patient, especially in the case of surgical debridement.
  • a wound is considered to be chronic if its healing is not completed within a period of four to eight weeks after its onset.
  • Chronic wounds are usually not accidental, but often occur in connection with diseases that are associated with weakened immune system or poor circulation.
  • Diseases associated with poor blood circulation, especially of the legs include, in particular, type 2 diabetes mellitus, chronic venous insufficiency or peripheral arterial occlusive disease, which is also known as the so-called "intermittent claudication".
  • a large-area, poorly healing and infected or necrotizing chronic wound can develop from very small wounds or bruises.
  • the wound care or wound treatment generally pursues the goal of preventing a wound infection and to ensure a rapid and functional wound healing. It depends on the severity, in particular the depth and area of the wound, how intense and by what measures wound healing must be supported.
  • EP 2 322 232 A2 describes a multilayer wound dressing which is based on a polysaccharide-containing gel and an additional layer based on a further biocompatible material.
  • wound dressings based on gels are associated with the disadvantage that only a reduced uptake of excess secretions can occur due to the already high moisture content of the gel.
  • such wound dressings in particular do not have sufficient bacteriostatic properties. see or bactericidal effect to ensure an efficient contamination protection against microorganisms.
  • DE 10 2007 030 931 A1 describes a wound dressing which, inter alia, has a disinfecting or decontaminating or protease-inhibiting substance. With a wound dressing of this type, however, sufficient odor adsorption can not be achieved. Above all, the protection against contamination due to the low bacteriostatic effect is not sufficient to efficiently prevent infections.
  • DE 10 2006 050 806 A1 describes wound dressings which comprise a carbonaceous material which is impregnated with noble metals, in particular silver, for the purpose of improving the bacteriostatic effect.
  • a carbonaceous material which is impregnated with noble metals, in particular silver, for the purpose of improving the bacteriostatic effect.
  • the wound dressings described above it is possible to achieve a better protection against contaminations.
  • there is a significantly increased risk of side effects due to the precious metals used since many precious metals, especially silver, are cell-like and are suspected of being involved in the diseases Alzheimer's and Parkinson's, since they can damage the isolation proteins on the nerves.
  • the noble metal-impregnated carbonaceous material does have antimicrobial effects, but wound healing can not be sustainably accelerated.
  • DE 38 75 217 T2 according to EP 0 31 1 364 B1 relates to a wound dressing which comprises an activated carbon layer in which at least 10% of the total pore volume of the activated carbon is to be formed by mesopores, said wound dressing being sterile and sterile should be included in a bacteria-proof envelope.
  • the activated carbon is advantageously impregnated with an antimicrobial agent such as silver.
  • an antimicrobial agent such as silver.
  • silver-impregnated activated carbon have been discussed previously.
  • a predominantly mesoporous activated carbon is not suitable for permanently immobilizing microorganisms, so that the bacteriostatic effect is not always sufficient.
  • this wound dressing has no wound healing promoting effect.
  • wound care dressings which have improved contamination protection, improved odor adsorption to remove unpleasant odors, and better uptake of excess secretions, particularly wound water.
  • the present invention has for its object to provide a wound dressing, which allows an optimized wound care, in particular based on the provision of an improved wound milieu.
  • the present invention proposes - according to one aspect of the invention - a wound dressing with a multilayer structure according to claim 1; Further advantageous embodiments of this aspect of the invention are the subject of the relevant subclaims.
  • a further subject matter of the present invention - according to one aspect of the invention - is also the use of a wound dressing for therapeutic wound care according to the invention according to the independent use claim; Further advantageous embodiments of this aspect of the invention are the subject of the relevant subclaims.
  • the present invention - according to a first aspect of the present invention - is thus a wound dressing, which is particularly suitable for the therapeutic wound care of the human or animal body, with multi-layered structure, wherein the multilayer structure at least one at least one hydrocolloid, preferably collagen containing layer (hereinafter also referred to as “hydrocolloid layer” or “collagen layer”) on the one hand and at least one activated carbon-containing layer (hereinafter also referred to as "activated carbon layer”) on the other hand.
  • the multilayer structure at least one at least one hydrocolloid, preferably collagen containing layer (hereinafter also referred to as “hydrocolloid layer” or “collagen layer”) on the one hand and at least one activated carbon-containing layer (hereinafter also referred to as "activated carbon layer”) on the other hand.
  • wound dressing as used in the context of the present invention, it generally refers in particular to dressings for topical application to external wounds in order to prevent the entry of foreign bodies into the wound and to absorb blood and wound secretions. Synonyms can also be used according to the invention terms such as "wound plaster", “wound dressing” or "wound cover”.
  • the activated carbon contained in the wound dressing is in particular a bacteriostatic or antimicrobial component which inhibits the growth of bacteria and thus effectively prevents the spread of bacteria in the wound to be treated.
  • an activated carbon having a special biostatic or biocidal, in particular antimicrobial action, which effectively prevents the growth of microorganisms, in particular of bacteria, in the wound is used.
  • the activated carbon used according to the invention in particular with a high micropore content, causes the microorganisms to be permanently bound or immobilized (which ultimately leads to their destruction, since the immobilization of both the microorganisms themselves and the possible nutrients on the activated carbon provides sufficient nutrient supply in derogation).
  • activated carbon can absorb or bind large amounts of wound water, so that the formation of waterlogging in the wound is prevented. Furthermore, the activated carbon allows the adsorption of unpleasant odors, as they occur especially in large-scale and necrotizing tissue interruptions.
  • the activated carbon also absorbs and destroys topical and sometimes wound-inhibiting or even toxic degradation products, as they arise on the one hand from the metabolic products associated with wound healing and on the other hand as a result of wound infections.
  • the activated carbon can also serve as a moisture buffer: Excess water or excess moisture can be temporarily stored or buffered and, if necessary, given off again, so that an ideal surrounding environment for the healing process of the wound is obtained. de is guaranteed, in which on the one hand with very good ventilation of the wound drying of the wound, but on the other hand also an excessively humid environment is counteracted; In this way, an ideal humidity environment for the healing process is provided.
  • the activated carbon is associated with no side effects and in particular is completely toxicologically harmless.
  • the hydrocolloid layer, in particular collagen layer, contained in the wound dressing also has special significance with regard to the wound healing process or wound care in the various phases of wound healing:
  • the hydrocolloid layer is, in particular, a wound-covering layer, which term is to be understood as meaning that it is a layer facing the wear and / or application state of the wound to be treated.
  • the wound-covering layer rests at least essentially on the entire area of the wound to be treated or is at least essentially in contact with the wound to be treated at least substantially over its entire area. It is thus an essential component of the wound dressing for the primary absorption of wound water on the one hand and for the protection of the wound from mechanical impact on the other.
  • processes of the body's own physiological wound healing are promoted by the hydrocolloid layer, in particular the collagen layer.
  • the hydrocolloid layer preferably the collagen layer
  • a moist-warm wound environment is maintained, which supports the wound healing to the effect that, in particular for enzymatic processes, as they are necessary for efficient wound healing, an accelerating and optimal environment is created.
  • the autolytic (ie endogenous) debridement of already dead tissue is promoted, which significantly reduces the risk of the need to perform, for example, surgical debridement.
  • the hydrocolloid preferably collagen
  • unfolds within the first hour after wounding has occurred Effect as a hemostat and causes by attaching the hydrocolloid fibers, especially the collagen fibers, platelets to the wound that the bleeding comes to a standstill faster.
  • the formation or immigration of macrophages is supported by the collagen, so that foreign bodies or germs that have entered the wound can be rendered harmless faster and more efficiently.
  • activated carbon layer on the one hand and hydrocolloid layer, preferably collagen layer, on the other hand leads in a completely surprising way to a synergistic effect with respect to wound healing, since the two components - activated carbon on the one hand and hydrocolloid, in particular collagen, on the other hand - in their effect in the context of wound healing While the activated carbon acts biostatically or biocidal, in particular antimicrobial or bacteriostatic, and realizes the previously described modes of action, the hydrocolloid or collagen component achieves a wound-healing-promoting or wound-healing-promoting action, i. H. actively promoted the wound healing process.
  • activated carbon layer on the one hand and hydrocolloid, in particular collagen layer, on the other hand complement one another as part of their common use in the wound dressing according to the invention.
  • the mutual effect enhancement of these two components is such that z. B. on a precious metal impregnation, such as in the prior art often realized silver metal impregnation, the activated carbon in the context of the present invention can be dispensed with entirely without this suffers the effective efficiency of the wound dressing according to the invention; This was not to be expected in this way, but was surprisingly found only by the applicant in the context of their studies.
  • a wound dressing is provided for the first time, which significantly accelerates wound healing, in particular that of complex or complicated wounds to be treated or chronic, but in addition is particularly well tolerated and offers excellent protection against contamination.
  • the application of the wound dressing according to the invention leads to an accelerated decrease in the exudation and to a rapid entry of the granulation phase, in which the new formation of tissue already takes place, so that rapid wound closure can take place.
  • improved wound healing it is already possible to refer to the application and efficacy studies carried out by the Applicant, which prove the excellent effectiveness, which will be discussed in detail later.
  • the combination of a hydrocolloid material, in particular collagen material, with activated charcoal has proved to be particularly advantageous, since the effect synergistically complements both materials, since the activated carbon as such is supported by its biocidal and / or biostatic, in particular its Antimicrobial or bacteriostatic effect and their ability to store moisture controlled and sometimes bind toxic degradation products, the wound healing and reduces the risk of infection.
  • the activated carbon used according to the invention physically binds wound water and microorganisms, whereas the hydrocolloid, in particular the collagen, supports wound healing in a complementary manner by providing optimal physiological conditions for wound healing.
  • the wound dressing according to the invention offers excellent protection against infection even against typical hospital germs, such as Staphylococcus aureus, Staphylococcus epidermidis, Proteus mirabilis, Escherichia coli and Pseudomonas aeruginosa, as is evident from the inhibition test carried out in the context of the embodiments according to the invention.
  • the wound dressing of the present invention provides an excellent basis for the therapy of wounds infected with multidrug-resistant strains without the use of antibiotics. This is especially true for patients with already weakened immune system of advantage, since the administration of numerous antibiotics burden the immune system even more.
  • a reduced use of antibiotics for therapeutic purposes generally contributes to curbing the development and spread of multidrug-resistant bacteria.
  • the wound dressing according to the invention offers the advantage that, due to the use of activated carbon, it can absorb the exudate or wound water, as it escapes in particular from large wounds, in large quantities. This ensures that in the wound, although the necessary for a good wound healing moist environment is maintained, the formation of waterlogging - which in turn would delay wound healing and increase the risk of infection - but is suppressed and toxic degradation products are removed. Not only the exudate and degradation products are absorbed, but also the degradation products are neutralized with the help of activated carbon by immobilization or degradation.
  • the wound dressing according to the invention is further distinguished by its extremely good compatibility with at the same time good contamination protection.
  • a good disinfecting or antimicrobial effect is often achieved only by the use of noble metals, in particular silver.
  • the topical use of such metals is extremely questionable in terms of health, since silver in particular is cell-like and is suspected of being involved in the triggering of diseases such as Alzheimer's or Parkinson's.
  • the use of activated carbon in combination with a hydrocolloid, preferably collagen already results in an ef- achieved effective contamination protection, which allows effective prevention and treatment of wound infections.
  • the wound dressing according to the invention is able to maintain a moist, warm environment during the treatment of the wound, in order to allow the tissue to be supplied with nutrients and to prevent it from drying out (namely, if the wound dries up, the tissue defect is destroyed by the death of cells) dehydration also slows down the healing process, as the defective cells impair the function of the immune cells and disrupt the enzyme activity during tissue regeneration.).
  • the temperature is also maintained with the wound dressing according to the invention at an optimum temperature for the physiological processes of wound healing.
  • the wound dressing according to the invention is permeable to gases and, moreover, allows the removal of excess, diseased and toxic components, such as are present in part in the wound water.
  • protection against contamination by the wound dressing according to the invention is of particularly high relevance, in order to prevent wound infections or to protect already infected wounds from the penetration of further microorganisms.
  • the wound dressing according to the invention has good adhesion with respect to the wound, without, however, sticking to the wound base.
  • the wound dressing of the invention is designed so that no fibers or other foreign substances can be delivered to the wound (which in turn could otherwise lead to inflammatory reactions).
  • an efficient wound dressing is provided whose particular effectiveness is based in particular on the targeted, in particular synergistic combination of a hydrocolloid layer on the one hand and an activated carbon layer on the other hand.
  • the wound dressing according to the invention can be designed in a variety of ways. Possible forms and configurations are illustrated below for better understanding: As far as the hydrocolloid of the hydrocolloid-containing layer is concerned, it is preferred according to the invention if it is selected from the group of polysaccharides and proteins, in particular plant, animal or bacterial polysaccharides and proteins.
  • the hydrocolloid is selected from the group of collagen, cellulose and cellulose derivatives, glycosaminoglycans (especially acid glycosaminoglycans, preferably hyaluronic acid and / or salts thereof), pectins, gum arabic, galactomannans, agar, carrageenan, alginates, gelatin, caseinates, xanthans , Dextrans and scleroglucans. It is particularly preferred if the hydrocolloid is collagen, hyaluronic acid and / or salts thereof and / or gelatin, very particularly preferably collagen.
  • hydrocolloid as used in the context of the present invention is concerned, it is to be understood very broadly.
  • hydrocolloids are at least partially understood to mean water-soluble, natural, but also synthetic polymers which form gels or viscous solutions or suspensions in aqueous systems. These are usually substances which belong to the substance classes of the proteins or polysaccharides, with a large number of hydrocolloids originating from nature, in particular from terrestrial plants, algae, animals and bacteria. Hydrocolloids are often used as thickeners in cosmetics and food industry products.
  • hydrocolloids For further details on the concept of the hydrocolloid, reference may be made in particular to Römpp Chemielexikon, 10th edition, Georg Thieme Verlag, Stuttgart / New York, keyword: "hydrocolloids", page 1837, including the literature cited therein, the contents of which are hereby incorporated by reference is included in full.
  • the hydrocolloid is gelatin and / or collagen, in particular collagen.
  • Collagen is a long fiber, linear colloid and high molecular weight skoprotein of the extracellular matrix found in connective tissue, especially in the skin, cartilage, tendons, ligaments and blood vessels, as well as the proteinaceous matrix of vertebrate bones also occur in phylogenetically early life forms, such as sponges or sea anemones.
  • the fibrous structure of the collagen is due, in particular, to the appearance of glycine at every third position in the amino acid sequence, since glycine, as a very space-saving amino acid, causes a special, helical secondary structure in proteins.
  • collagen has a protease-inhibiting effect, which serves to lower the wound healing-related increased protease level in the wound area. Namely, if the level of protease in the wound area is increased, this often leads to uncoordinated wound healing and to the destruction of growth factors, since these are degraded by proteases, such as, for example, neutrophilic elastases or matrix metalloproteases (MMPs).
  • proteases such as, for example, neutrophilic elastases or matrix metalloproteases (MMPs).
  • MMPs matrix metalloproteases
  • collagen stimulates the formation of vascular structures and connective tissue and thus helps restore the structural stability of the tissue. In this sense, by using collagen as the HydrokoUoid, wound healing can be promoted in a highly efficient manner.
  • gelatin which can also be used in a preferred manner in the wound dressing as HydrokoUoid:
  • gelatin is usually and within the scope of the present invention, a polypeptide, which is primarily by hydrolysis of the skin and bones of animals contained collagen under acidic or basic conditions understood. The recovery of gelatin under acidic conditions results in the so-called type A gelatin or under alkaline conditions in the so-called type B gelatin.
  • Gelatin In water, especially under the simultaneous influence of heat, gelatin swells up first and dissolves in it to form a viscous solution, which finally solidifies gelatinous below 35 ° C.
  • gelatin For further details on the term gelatin, reference may be made to Römpp Chemielexikon, 10th edition, Georg Thieme Verlag Stuttgart / New York, keyword: "gelatin", page 1484, and the literature reviewed herein, the entire contents of which are hereby incorporated by reference in their entirety is included.
  • the layer containing hydrocolloid, preferably collagen is based on a hydrocolloid fleece and / or hydrocolloid foam, preferably a collagen fleece and / or collagen foam.
  • a hydrocolloid and / or hydrocolloid preferably collagen and / or a collagen foam, porcine origin
  • hydrocolloid fleece or hydrocolloid foam preferably collagen fleece or collagen foam
  • hydrocolloid foam or hydrocolloid foam in particular collagen fleece or collagen foam
  • wound dressings based on hydrocolloid foam or hydrocolloid fleece, in particular collagen foam or collagen fleece do not give off any fibers or any solid constituents or particles or activated carbon to the wound, and thus the intrusion or an additional application is prevented by foreign bodies.
  • the wound dressing hydrocolloid foam, in particular collagen foam, d. H. to a foam solidified or expanded hydrocolloid or collagen, in particular because the pores contained in the hydrocolloid foam or collagen foam can also efficiently drain large amounts of wound water from the wound area, so that the formation of waterlogging and too long contact of contained in the wound water and the wound healing harmful substances with the wound itself is prevented.
  • the chemical and physical properties of solidified and expanded hydrocolloid or collagen i.e., hydrocolloid or collagen foam
  • foams are extremely adaptable to the shape of the wound base, d. H. they can cover the wound over the entire surface or area without bulges or the like arise.
  • a particularly good gas or air permeability is made possible by using a hydrocolloid foam or a collagen foam.
  • This is associated in particular with the advantage that the wound is well ventilated, in particular with oxygen, which on the one hand promotes the physiological wound healing processes, on the other hand prevents the growth of germs with anaerobic lifestyle, for example of the genus Clostridium.
  • the provision of the colloid layer or collagen layer on the one hand effectively dissipates wound water and on the other hand ensures good gas permeability.
  • hydrocolloid layer in particular the collagen layer
  • this is obtainable by applying a dispersion or solution of a hydrocolloid, preferably a collagen, to a carrier and subsequent drying, in particular lyophilization (freeze-drying), preferably below expansionary on the hydrocolloid, preferably collagen.
  • a hydrocolloid, preferably collagen suspension or solution which is suitable according to the invention is obtainable in particular by suspending or solubilizing the hydrocolloid, in particular collagen, in water, in particular ultrapure water or in disinfected or sterilized or sterilized water.
  • the hydrocolloid in particular collagen, preferably in an amount in the range of 0, 1 to 5 wt .-%, in particular 0.5 to 4 wt .-%, preferably 0.7 to 3 wt .-%, particularly preferably 1 up to 2% by weight, based on the hydrocolloid suspension or solution, preferably collagen suspension or solution, in the suspension or solution.
  • the dried and expanded hydrocolloid, preferably collagen may eventually be removed from the carrier and used to make the wound dressing.
  • the hydrocolloid or the corresponding layer with the hydrocolloid can have a defined residual moisture content, which is known to the person skilled in the art.
  • the hydrocolloid preferably the collagen, the hydrocolloid layer, in particular the collagen layer, may in particular be of porcine, bovine and / or equine origin, preferably of porcine origin, in particular of porcine skin.
  • a collagen material with the above properties is commercially available, in particular the medichema ® GmbH, Chemnitz, Germany.
  • the layer containing at least one hydrocolloid, preferably collagen is or forms an outer layer of the wound dressing.
  • the layer containing at least one hydrocolloid, preferably collagen, in the application or application state of the wound dressing is arranged on the side of the wound dressing facing the wound to be treated.
  • the layer containing at least one hydrocolloid, preferably collagen it preferably has a thickness in the range from 0.01 to 100 mm, in particular 0.02 to 50 mm, preferably 0.05 to 10 mm.
  • it is advantageous especially in the case of strong secretion of wound water (especially, for example, in the exudative phase of wound healing) - when the layer containing a hydrocolloid, preferably collagen, is particularly thick.
  • the layer containing a hydrocolloid, preferably collagen accounts for 5% to 95%, in particular 10% to 80%, preferably 20% to 60%, of the total thickness of the wound dressing.
  • the activated carbon contained in the wound dressing can - as will be explained below - be adapted by the very special selection of the respective requirements imposed on the wound dressing according to the invention.
  • the activated carbon contained in the wound dressing is preferably a granular, in particular spherical activated carbon and / or activated carbon fibers, in particular in the form of an activated carbon fiber surface structure, but preferably a granular, in particular spherical activated carbon.
  • a granular, in particular spherical activated carbon offers the advantage of a particularly good processability, in particular with regard to a fixation on a flat, preferably textile carrier, and on a good mechanical strength, so that no dust and no impurities are released.
  • the activated carbon-containing layer is a granular, in particular spherical activated carbon having absolute particle sizes in the range of 0.01 to 3 mm, in particular in the range of 0.02 to 2 mm, preferably in Range of 0.05 to 1.5 mm, more preferably in the range of 0, 1 to 0.8 mm, most preferably in the range of 0.2 to 0.6 mm.
  • the activated carbon-containing layer is a granular, in particular spherical activated carbon having average particle sizes, in particular determined according to ASTM D2862-97 / 04, in the range of 0.05 to 2.5 mm, in particular in the range of 0, 1 to 2 mm, preferably in the range of 0.15 to 1 mm, particularly preferably in the range of 0.2 to 0.6 mm.
  • the parameter data of the activated carbon used in accordance with the invention are determined or mediated by standardized or explicitly stated determination methods or determination methods familiar to the person skilled in the art. These parameters are given, unless stated otherwise below, in particular from the Stickstoffsorptionsisothermen the activated carbon.
  • the activated carbon of the activated carbon-containing layer formed by micropores with pore diameters of ⁇ 20 A microvoid fraction of at least 60%, in particular at least 65%, preferably at least 70%, based on the total pore volume of the activated carbon.
  • the activated carbon of the activated carbon-containing layer has a micropore volume fraction formed by micropores with pore diameters of ⁇ 20 A, based on the total pore volume of the activated carbon, in the range of 60% to 95%, in particular in the range of 65% to 90%. , preferably in the range of 70% to 85%.
  • the remaining pore volume fraction of the activated carbon used is concerned, it is formed by meso and macropores.
  • micropores refers to pores having pore diameters up to 20 ⁇ inclusive
  • mesopores refers to pores having pore diameters of> 20 ⁇ to 50 ⁇ inclusive
  • macropores to pores having pore diameters> 50 ⁇ designated. Due to the high micropore content, in particular a better sorption of wound water and odors can be achieved. In addition, the bacteriostatic or antimicrobial action against activated carbon with a high proportion of meso and macropores is significantly improved. In addition, an activated carbon with a high micropore content has the advantage that microorganisms can be permanently bound or immobilized.
  • the activated carbon of the activated carbon-containing layer is a micropore volume formed by micropores with pore diameters of ⁇ 20 ⁇ , in particular a micropore volume after carbon black of at least 0.40 cmVg, in particular at least 0.45 cm / g , preferably at least 0.50 cm Ig.
  • the activated carbon of the activated carbon-containing layer comprises a micropore volume formed by micropores with pore diameters ⁇ 20 ⁇ , in particular a micro pore volume after carbon black, in the range from 0.40 cm 3 / g to 2 cm 3 / g, in particular in the range of 0.45 cm 3 / g to 1, 5 cm 3 / g, preferably in the range of 0.50 cm 3 / g to 1, 2 cm 3 / g.
  • the carbon black determination method is known per se to a person skilled in the art, so that no further details are required in this regard.
  • the activated carbon of the activated carbon-containing layer has a specific micropore surface fraction, in particular a micropore surface fraction formed of pores with pore diameters of ⁇ 20 ⁇ , of at least 50%, in particular at least 60%, preferably at least 70%, most preferably at least 75%, based on the specific total surface area (BET) of the activated carbon has.
  • a specific micropore surface fraction in particular a micropore surface fraction formed of pores with pore diameters of ⁇ 20 ⁇ , of at least 50%, in particular at least 60%, preferably at least 70%, most preferably at least 75%, based on the specific total surface area (BET) of the activated carbon has.
  • the activated carbon of the activated carbon-containing layer has an inner surface area (BET) in the range from 500 to 3,000 m 2 / g, in particular in the range from 800 to 2,000 m 2 / g, preferably in the range from 900 to 1,800 m 2 / g, more preferably in the range of 1,000 to 1,600 m 2 / g.
  • BET inner surface area
  • All BET surface area information refers to the determination according to ASTM D6556-04.
  • MP-BET multi-point BET determination method in a partial pressure range p / ⁇ of 0.05 to 0.1 is used to determine the BET surface area.
  • the activated carbon of the activated carbon-containing layer has a total pore volume, in particular a total pore volume according to Gurvich, in the range of 0, 1 to 4 cm 3 / g, in particular in the range of
  • 0.2 to 3 cm Ig preferably in the range of 0.3 to 2.5 cm Ig, particularly preferably in the range of 0.5 to 2 cm 3 / g.
  • Gurvich As far as the determination of the total pore volume according to Gurvich is concerned, it is a measurement or determination method known per se to a person skilled in the art. For further details concerning the determination of the total pore volume according to Gurvich, for example, See, for example, L. Gurvich (1915), J. Phys. Chem. Soc. Soot. 47, 805, and to S. Lowell et al., Characterization of Porous Solids and Power: Surface Area Pore Size and Density, luwer Academic Publishers, Article Technology Series, pp. 11, 1 et seq.
  • the activated carbon is such that at least substantially no particles or dust are released into the environment.
  • the activated carbon has a compressive and / or bursting strength, in particular a weight load per activated carbon particle, in particular per activated carbon particle or activated carbon sphere, of at least 10 Newton, in particular at least 1 Newton, preferably at least 20 Newton.
  • the activated carbon a pressure and / or bursting strength, in particular a weight load per activated carbon particles, in particular per activated carbon grain or activated carbon ball, in the range of 10 to 50 Newton, in particular in the range of 12 to 45 Newton, preferably in Range from 15 to 40 Newtons.
  • the activated carbon is at least essentially abrasion-resistant and / or at least substantially dust-free.
  • the excellent abrasion resistance and dust-free nature of the activated carbon used make it possible that the wound to be treated is not contaminated by materials or contaminants (such as activated charcoal dust) of the wound dressing.
  • the abrasion resistance of the activated carbon used according to the invention should be extremely high:
  • the abrasion resistance of the activated carbon according to the invention is according to the method according to CEFIC (Conseil Europeen of Federations l'Industrie Chimique Avenue Louise 250, Bte 71, B - 1050th Brussels, November 1986, European Council of Chemical Manufacturers' Federations, test methods for activated carbons, point 1.6 "Mechanical Hardness", pages 18/19) advantageously at 100%.
  • CEFIC Conseil Europeen of Federations l'Industrie Chimique Avenue Louise 250, Bte 71, B - 1050th Brussels, November 1986, European Council of Chemical Manufacturers' Federations, test methods for activated carbons, point 1.6 "Mechanical Hardness", pages 18/19
  • ASTM D3802 abrasion resistance of the activated carbon used according to the invention should also be 100%.
  • the activated carbon of the activated carbon-containing layer has a fractal dimension of the open porosity of at least 2.3, in particular of at least 2.4, preferably of at least 2.5, more preferably of at least 2.7.
  • the fractal dimension of the open porosity can be determined in particular according to WO 2004/046033 Al or DE 102 54 241 A1 and characterizes in particular the roughness, in particular microroughness, of the inner surface of the activated carbon. This value is thus to be regarded as a measure of the microstructuring of the inner surface of the activated carbon.
  • Improvement of the binding comprises, on the one hand, an increase in the packing density within an adsorbed monolayer (and thus an increase in the adsorption capacity) and, on the other hand, an increased bond strength.
  • an activated carbon having such values for the fractal dimension of the open porosity species, such as in particular microorganisms, toxins, etc., in the context of the wound dressing according to the invention, to a greater extent, in particular with improved loading or capacity and with greater irreversibility, sorptive or be adsorptively bound.
  • biocidal properties it is to be understood that microorganisms in particular are killed and / or degraded by the biocidal properties.
  • microorganisms are understood as meaning both bacteria and fungi, but also viruses.
  • Biocidal properties in the sense of the present invention are thus equally bactericidal, understood fungicidal and / or virucidal properties.
  • biostatic properties By “biostatic properties”, however, microorganisms, especially bacteria, fungi and viruses, are primarily inhibited in their growth or in their multiplication. For the purposes of the present invention, biostatic properties are thus understood to be equally bacteriostatic, fungistatic and / or virustatic properties.
  • the activated carbon of the activated carbon-containing layer has a biocidal and / or biostatic, in particular antimicrobial action and / or equipment.
  • the activated carbon to be used for this purpose as such it is advantageous to use synthetic or synthetically produced activated carbon.
  • the biocidal and / or biostatic, in particular antimicrobial action and / or equipment of the activated carbon may be provided according to the invention by the production process of the activated carbon, in particular the production by means of pyrolysis and subsequent activation of organic polymers.
  • the effect and / or equipment of the activated carbon described above results, in particular, as a result of the surface charge and / or hydrophobicity and / or textural properties generated during the production process.
  • the starting polymers for the preparation of the activated carbon are concerned, these may in particular be polystyrenes, preferably divinylbenzene-crosslinked polystyrenes.
  • the outstanding antimicrobial effectiveness of the activated carbon used according to the invention is based on the fact that the properties described above, in particular in combination with a high microporous volume, are particularly responsive to polarities of (bio) molecules and (bio) particles.
  • the activated carbon used according to the invention is designed in particular in such a way that, in particular, there is an affinity for the molecules anchored in and / or on the cell wall of the microorganisms .
  • the biocidal and / or biostatic, in particular antimicrobial action and / or equipment of the activated carbon in particular, it may also be optimized by additional equipment, in particular impregnation, of the activated carbon with at least one biocidal and / or biostatic, in particular antimicrobial, active ingredient as defined below, carried out or thereby be increased.
  • the additional equipment, in particular impregnation, of the activated carbon with at least one biocidal and / or biostatic, in particular antimicrobial active substance the inherent biostatic or biocidal, in particular antimicrobial, properties of the activated carbon inherent in the production process of the activated carbon are additionally per se reinforced antimicrobial properties of the active substance.
  • the equipment, in particular impregnation, of the activated carbon takes place in a manner known per se to the person skilled in the art, for example by contacting the activated carbon with the intended active substance or a solution and / or dispersion containing the active substance. Such contacting can be done, for example, by spraying, slurrying, soaking and the like.
  • the activated carbon used according to the invention is generally free of metal impregnations.
  • metal impregnations eg based on silver or silver ions
  • the combination with the hydrocolloid layer, preferably a collagen layer nevertheless ensures good efficiency.
  • An activated carbon having the abovementioned properties is commercially available, in particular via Blücher GmbH, Erkrath / Federal Republic of Germany, or Adsor-Tech GmbH, Premnitz / Federal Republic of Germany.
  • the amounts of activated carbon used can vary within a wide range:
  • the activated carbon of the activated carbon-containing layer in an amount, in particular Aufla- amount of 1 to 1,000 g / m, in particular 5 to 500 g / m, preferably 10 to 400 g / m, preferably 20 to 300 g / m, particularly preferably 25 to 250 g / m 2 , is present.
  • the activated carbon of the activated carbon-containing layer is arranged on a flat, preferably textile support, preferably attached thereto or fixed is.
  • the activated carbon of the activated carbon-containing layer is disposed on a three-dimensional, preferably porous and / or textile support, preferably a foam or foam, preferably attached thereto or fixed or incorporated herein.
  • the three-dimensional support is formed on the basis of an elastomeric resin or based on a polyurethane.
  • the advantage of the aforementioned (carrier) materials is in particular that they are particularly permeable to air, which benefits the healing process.
  • aeration of the wound is of particular relevance with regard to the provision of oxygen in the wound area and the prevention of the growth of anaerobic bacteria.
  • the activated carbon of the activated carbon-containing layer is arranged between a first textile sheet material and a second textile sheet material.
  • the activated carbon is present in the form of a loose filling in the wound dressing, as it were.
  • the bed is present or introduced between a first textile sheet material and a second textile sheet material.
  • the loose bed of activated carbon can also be present between the hydrocolloid layer and an outer covering layer.
  • the activated carbon is introduced into a textile sheet material and, as it were, is present in the wound dressing as an "activated carbon cushion" which contains activated carbon in bulk.
  • the textile sheet material used according to the invention is in the form of woven, knitted or knitted fabric, scrim, nonwoven fabric or filamentary fiber material, in particular as filamentary fiber material.
  • PET polyesters
  • Polyolefins in particular polyethylene (PE) and / or polypropylene (PP), polyvinyl chloride (PVC); Polyvinylidene chloride (PVDC); Cellulose acetate (CA); Cellulose triacetate (CTA); Polyacrylic (PAN); Polyamide (PA); Polyvinyl alcohol (PVAL); Poly
  • first textile sheet material and / or the second textile sheet material at least substantially no fibers and / or at least substantially no activated carbon can release, so that the wound is not contaminated by the fiber material or no foreign body in invade the wound.
  • the activated carbon of the activated carbon-containing layer is attached to the first textile planar material and / or to the second textile planar material, in particular by means of a preferably medically and / or physiologically compatible adhesive.
  • the adhesive is discontinuous and / or point-wise applied to the first and / or second textile sheet material, so that a good gas and air permeability of the sheet material is ensured, and also the activated carbon is not completely covered with adhesive and thus remains easily accessible.
  • the adhesive it is preferred if it is applied to the first and / or second textile sheet material in a quantity of 1
  • the adhesive covers the first and / or second textile sheet material to not more than 70%, in particular not more than 60%, preferably not more than 50%, preferably not more than 40%, more preferably not more than 30% ; In this way, a secure and stable fixation of the activated carbon is still ensured good accessibility for the substances to be adsorbed and high gas or air permeability.
  • the adhesive should be used in such an amount and / or with such a condition that the surface of the activated carbon is at least 50%, in particular at least 60%, preferably at least 70% not covered with adhesive or is freely accessible; In this way, as stated above, a secure fixation or attachment of the activated carbon and a high efficiency of the activated carbon ensured.
  • the activated carbon is present as a self-supporting layer, in particular as activated carbon fiber sheet or as a self-supporting, flat or three-dimensional, preferably continuous structure of interconnected and / or mutually attached granular, in particular spherical, activated carbon particles.
  • the activated carbon in the layer containing hydrocolloid, preferably collagen, and / or to attach and / or fix it to the layer containing hydrocolloid, preferably collagen.
  • the activated carbon-containing layer does not necessarily have to be continuous layers.
  • the activated carbon is incorporated into a further, in particular separate and / or additional layer and / or fixed thereto.
  • This separate and / or additional layer which is a constituent of the wound dressing according to the invention, may additionally contain further components, in particular at least one active ingredient, in particular as will be described below.
  • the surface of the activated carbon of the activated carbon-containing layer is at least 50%, in particular at least 60%, preferably at least 70%, freely accessible and / or not covered. This is - regardless of the form or layer in which the activated carbon is present - usually realized in the wound dressing of the invention.
  • the individual layers of the wound dressing are each connected to one another or if the individual layers of the wound dressing form a composite, so that sufficient stability is ensured when the wound dressing is applied and / or applied is.
  • the wound dressing further comprises at least one active ingredient, which may in particular be selected from the group of antimicrobial agents acting active ingredients, disinfecting agents, anti-inflammatory agents, hemostatic agents and wound healing agents.
  • the wound dressing is equipped with at least one antimicrobial and / or disinfecting and / or anti-inflammatory and / or hemostatic and / or wound healing promoting agent or that the wound dressing has at least one antimicrobial and / or disinfecting and / or hemostatic and / or wound healing and / or anti-inflammatory agent.
  • the wound dressing has at least one antimicrobial and / or disinfecting and / or hemostatic and / or wound healing and / or anti-inflammatory agent.
  • the active substance has biocidal and / or biostatic action, in particular bactericidal or bacteriostatic and / or fungicidal or fungistatic and / or virucidal or virustatic action.
  • pathogens such as bacteria, fungi or viruses can be inhibited not only in their growth, but also be actively killed.
  • the active ingredients to be used are concerned, it has proved to be particularly effective when the active ingredient is an antiseptic and / or disinfectant.
  • a disinfectant is understood as meaning, in particular, chemical agents which serve to kill pathogenic agents on organisms and objects.
  • the spectrum of action of disinfectants generally includes pathogenic microorganisms, to which bacteria, viruses, spores, small and mold fungi are counted in this connection.
  • antiseptic As far as the term "antiseptic” is concerned, it also refers to germicidal agents with which in particular wounds, skin and mucous membranes and medically used objects are treated in order to achieve a high level of sterility.
  • the active ingredient in particular the disinfectant, is selected from the group of polyhexamethylene biguanide (polyhexanide), taurolidine, benzalkonium chloride, chlorhexidine, octenidine and their physiologically acceptable salts and derivatives and mixtures thereof, preferably from octenidine and or polyhexamethylene biguanide (polyhexanide).
  • the aforementioned active substances, in particular octenidine and polyhexanide are particularly well tolerated and have a broad spectrum of activity against numerous pathogens.
  • side effects such as those associated with silver or other precious metals using as a bacteriostat, can be prevented by the use of the aforementioned active substances.
  • the additional use of a disinfectant is associated in particular with the advantage that - without wishing to be limited to this theory - wound healing can be accelerated by a further reduction in the infection rate or by a reduction in bacterial infestation.
  • the disinfectant octenidine used according to the invention can be used in particular in the form of the broad-spectrum antiseptic octenidine dihydrochloride.
  • octenidine belongs to the group of quaternary ammonium compounds. Octenidine is particularly well tolerated on skin, minimizing the occurrence of side effects.
  • octenidine has a very broad spectrum of activity, which includes both Gram-positive and Gram-negative bacteria as well as a variety of viruses and fungi.
  • polyhexanide can be used as a disinfectant in the context of the present invention.
  • This is a disinfectant from the group of biguanides, which generally have a hydrophobic backbone with several cationic Biguanid phenomenon, the number of biguanide residues in the molecule is variable and its antimicrobial or bacteriostatic Effectiveness influenced.
  • Polyhexanide or polyhexanide solutions is or are thus present in the form of mixtures based on polymers having different molecular sizes.
  • the number of biguanide residues per molecule is generally in the range of 2 to 40.
  • the individual biguanide residues are separated from one another via a hexamethylene chain.
  • polyhexanide acts as a strong base due to the protonation of the biguanide radicals in the neutral pH range.
  • the strong base effect - again without wishing to be limited to this theory - causes the polyhexanide molecules to interact with the negatively charged cell membrane of the underlying pathogenic microorganisms through electrostatic interactions, which leads to a destabilization or disintegration of the cellular structures Can cause cell death.
  • polyhexanide as a disinfectant has a largely nonspecific mode of action, so that it can be inhibited in their growth even difficult to inhibit germs, such as Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa and Escherichia coli in an efficient manner.
  • germs such as Staphylococcus aureus, Bacillus subtilis, Pseudomonas aeruginosa and Escherichia coli in an efficient manner.
  • polyhexanide is also effective antiviral and antifungal.
  • polyhexanide Another advantage associated with the use of polyhexanide, is also that due to the nonspecific mode of action, in contrast to antibiotics generally no resistance results.
  • polyhexanide, with its broad antimicrobial efficacy is also characterized by excellent tolerance and (tissue) compatibility, so that it can be used over a longer period of time.
  • polyhexanide also accelerates wound healing, in particular due to a reduced bacterial infestation or a reduced infection rate.
  • the disinfectant in particular polyhexanide
  • at least one viscosity-increasing and / or matrix-forming Substance in particular based on an organic polymer, preferably a polyalkylene glycol, preferably polyethylene glycol and / or polypropylene glycol, is used.
  • an organic polymer preferably a polyalkylene glycol, preferably polyethylene glycol and / or polypropylene glycol
  • Such a substance may be, the commercially available Macrogolum ® 4000 in particular. As a result, the effective efficiency of the disinfectant can be further increased.
  • the active substance is a wound-promoting active substance, which in particular can be selected from the group of alginates, chitosan, hyaluronic acid and its salts, allantoin, beta-sitosterol, bromelain, dexpanthenol , Pantothenic acid, urea, flavonoids, riboflavin, saponins, cineole, tocopherol and mixtures thereof.
  • the amount of active ingredient used can vary within wide ranges.
  • an amount of active ingredient, in particular amount of support of 0.00001 to 5 g / cm 2 , in particular 0.0001 to 2 g / cm 2 , preferably 0.001 to 1 g / cm, more preferably 0.01 to 0.5 g / cm can be achieved.
  • the active ingredient is present in the layer containing a hydrocolloid, preferably collagen, and / or in the activated carbon-containing layer.
  • the active ingredient may in each case be incorporated either only in the layer containing a hydrocolloid, preferably collagen, or else alternatively only in the activated carbon-containing layer.
  • the introduction of the active substance into the hydrocolloid or collagen layer leads to a direct release of the active ingredient from the hydrocolloid or collagen layer into the wound, while the introduction of the active substance into the activated carbon layer has the advantage that the active substance present in the activated carbon layer is retarded or released in a controlled manner over an extended period of time or released to the wound (ie a depot effect is achieved as it were).
  • particularly preferred according to the invention is the introduction of the active substance into both the hydrocolloid or collagen layer and into the activated carbon layer.
  • This embodiment is associated in particular with the advantage that in this way a double effect can be generated as it were, since the release of the active substance from the hydrocolloid or collagen layer takes place directly or directly into the wound, while those present in the activated carbon layer Active ingredients can be released in a delayed manner, as a result of which a supply of the wound with the respective active substance can be ensured over a prolonged period with a controlled release amount.
  • the active ingredient - at least partially - into other layers of the wound dressing than the layer containing the activated carbon or the layer containing the hydrocolloid, preferably collagen, if such layers are present (eg in the optional textile carrier or carrier layers, etc.).
  • the layer containing the activated carbon or the layer containing the hydrocolloid, preferably collagen if such layers are present (eg in the optional textile carrier or carrier layers, etc.).
  • the active substance As far as the introduction of the active substance into the hydrocolloid or collagen layer is concerned, it can be incorporated directly into the solution or dispersion during the production of the hydrocolloid or collagen layer.
  • the introduction of the active ingredient in the activated carbon layer can be effected in particular by contacting, preferably impregnating, the activated carbon with the active ingredient or a drug solution.
  • the active substance is present in the hydrocolloid layer, preferably collagen layer, and / or activated carbon layer
  • the active substance is incorporated or incorporated in the respective layer, in particular in or on the respective layer is fixed, preferably reversibly fixed, and thus preferably released again on contact with the wound or with water or moisture, or is released to the wound.
  • the wound dressing is equipped with at least one substance which has protease activity.
  • the substance having protease activity is present in the hydrocolloid or collagen layer and / or in the layer provided with activated carbon.
  • FIG. 1 is a schematic sectional view through the layer structure of a wound dressing according to a first preferred embodiment of the present invention according to a specific embodiment
  • Fig. 2 is a schematic sectional view through the layer structure of a wound dressing according to another preferred embodiment of the present invention according to another specific embodiment.
  • Fig. 1 shows a schematic sectional view through the layer structure of a wound dressing 1 according to the invention according to a specific embodiment of the present invention.
  • the wound dressing 1 according to the invention in particular suitable for therapeutic wound care, has a layer 3 containing activated carbon and a layer 2 containing collagen, wherein the collagen layer 2 in the state of use represents the wound-facing layer.
  • the wound dressing 1 may have an adhesive edge 5, which, on the one hand, makes it possible to fix the wound dressing 1 when it is used, in particular on the skin, and, on the other hand, holds the individual layers 2, 3 together.
  • the layers described above are formed as a composite.
  • FIG. 2 shows a schematic sectional view through the layer structure of a wound dressing 1 according to the invention in accordance with a further specific embodiment.
  • the wound dressing 1 according to the invention which is particularly suitable for therapeutic wound care, has an activated carbon-containing layer 3, the activated carbon being arranged between two textile carrier materials 4a and 4b, in particular fixed thereto, and the textile carrier material 4b is a first outer layer of the wound dressing 1 forms.
  • the wound dressing 1 according to the invention has a collagen-containing layer 2, which constitutes the second outer layer of the wound dressing 1 according to the invention, the collagen layer 2, in the state of use, being the layer facing the wound.
  • the layers described above are formed as a composite.
  • a wound dressing with bi- oziden and / or biostatic, in particular antimicrobial and wound-promoting properties is thus provided, wherein the abovementioned properties are ensured, in particular, by a biostatic or biocidal, in particular antimicrobially active, activated carbon.
  • the activated carbon can inactivate or kill pathogens (such as fungi, bacteria and viruses), as these also adhere to the activated carbon. In this way, the bacterial load or germ count in wounds is effectively and permanently minimized.
  • the concentration of other antimicrobial agents can be reduced or their use can be dispensed with altogether, which correspondingly leads to a reduction of the toxicological potential of the wound dressing.
  • the wound healing in particular by the binding of the toxins, by the exudate management to maintain the optimal for the wound healing moist-warm conditions and promoted by an effective gas exchange.
  • the effectiveness can be increased or optimized by also other (active) substances, eg. B.
  • the present invention thus provides in particular a wound dressing with a biocidal or biostatic, in particular antimicrobial activated carbon;
  • a biocidal or biostatic, in particular antimicrobial activated carbon is able - in some cases even without the additional use of an antimicrobial agent - in addition to the adsorption of toxins and odors equally pathogens (eg., Fungi, bacteria and viruses) to permanently inactivate or kill.
  • pathogens eg., Fungi, bacteria and viruses
  • wound healing is promoted because the use of the activated carbon allows purification of the exudate by the adsorption of toxins.
  • the activated carbon acts as a sort of sorption storage for the exudate, so that it can be taken up to maintain a moist but not wet wound environment, but can also be returned to the wound.
  • the targeted delivery of additional active ingredients from the activated carbon is possible. Good gas exchange via the wound dressing further accelerates wound healing processes.
  • the activated carbon according to the invention having biostatic or biocidal, in particular antimicrobial properties is thus capable of binding on the one hand toxins and odorous substances and on the other hand also acting as a protection against contamination.
  • the mode of action of the activated carbon will now be described in more detail below, wherein the following statements are not intended to limit the present invention in any way:
  • the activated carbon is capable of killing or permanently inactivating pathogens (eg fungi, bacteria and viruses) because they adhere to it and thus become immobilized.
  • pathogens eg fungi, bacteria and viruses
  • the immobility or immobilization generated in this way prevents the multiplication of the pathogens;
  • any pathogens are deprived of nutrients by the strong attractions of activated carbon, which are also immobilized and are no longer accessible to the pathogens.
  • the activated carbon causes damage to the cell membrane and the cell wall of the pathogens due to the strong interactions.
  • the excellent adsorption capacity of the activated carbon is due, in particular, to the texture properties of its (inner) surface, in particular due to electrostatic interactions and van der Waals forces. The effects mentioned cause a long-term reduction of the bacterial load or germ count in the wound and, as a result, a minimization of the risk of contamination.
  • the biostatic or biocidal, in particular antimicrobially active, activated carbon can be contained in one or more layers of the wound dressing.
  • the active sole can be separated, for. B. as a finish, be present on a textile sheet material in the wound dressing.
  • the textile sheet material can be used selectively for the modulation or adjustment of gas and liquid permeability via the choice of the polymers or of the filaments, fibers and yarns resulting therefrom. This is particularly important in relation to the different stages of wound healing, as these in part provide different conditions for the moisture content and the gas composition in the wound area.
  • the activated carbon in the form of a pad is completely enveloped by a textile sheet material and is attached thereto with an adhesive fix. This prevents the activated carbon from dissolving out.
  • a textile sheet material in the form of a knitted fabric it can be ensured in this connection that the wound dressing is still permeable and that pathogens with the wound exudate reach the antimicrobially active charcoal.
  • nonwovens or fabrics can be used. If the textile surface material comes into direct contact with the injury, according to the invention a yarn which does not adhere to the wound is used in order to avoid injuries during dressing changes.
  • Such a layer can be equipped with various substances - which are important for the healing process and as they have been explicitly stated before.
  • a layer with Wundhei- promoting substances such as Alginate, chitosan or hyaluronic acid. But it is also possible to add other substances such. Allan- toin, beta-sitosterol, urea, bromelain, dexpanthenol, flavonoids, riboflavin, saponin, cineole, tocopherol and other substances of this kind.
  • the textile sheet adheres to a layer of resorbable hydrocolloid, in particular collagen, which fulfills several functions in this context:
  • a collagen layer compensates for unevenness due to its foamy, soft structure.
  • the distance between the wound and the antimicrobial activated carbon is reduced, which increases their effectiveness.
  • a high capillary activity is created which makes it possible to take up and transfer large quantities of liquid, in particular wound water.
  • a moist wound environment is provided which prevents maceration hindering wound healing.
  • the exudate flow out of the wound and out to the activated carbon is ensured and excess moisture is released in the form of water vapor.
  • Impurities, proteases and free radicals are bound by the activated carbon as well as by such a collagen layer in different ways and removed from the wound.
  • the biostatic or biocidal, in particular antimicrobial properties of the activated carbon also prevent the formation of a biofilm or a bacterial layer and allow a stable, long-lasting purification process of the wound exudate. If a biofilm were to be formed, this would also be detrimental to wound healing insofar as the contact of the liquid with the activated carbon was prevented and in this way the gas exchange would be prevented. Since the biostatic or biocidal, in particular antimicrobial effect is provided by the activated carbon as such, the generation of a contamination protection by reduced oxygen supply is not required, as has to be realized many times in the prior art. The increased gas exchange in the context of the present invention as well as the improved exudate management ensure overall improved wound healing.
  • the wound dressing according to the invention may contain an additional, in particular antimicrobial, active ingredient in order to support the mode of action of the activated carbon in a synergistic mode of action.
  • an additional, in particular antimicrobial, active ingredient in order to support the mode of action of the activated carbon in a synergistic mode of action.
  • This may in particular be polyhexamethylene biguanide (PHMB), chlorhexidine or octenidine, although any other antiseptic and / or disinfectant may be used, such as chitosan or triclosan.
  • the wound dressing may also be provided to equip the wound dressing with antibiotics.
  • the respective active ingredient is dissolved out of the wound dressing, diffuses into the wound and unfolds its activity in the entire wound area. This also allows for inactivation of microorganisms in wound wells.
  • the activated carbon used according to the invention it is ensured that even in the case of complete detachment of the active substance from the wound dressing, the biostatic or biocidal, in particular antimicrobial action is still sufficient to prevent recontamination of the wound. This represents an unsolved problem in the prior art.
  • the wound dressing according to the invention it is possible in particular by means of the wound dressing according to the invention to reduce or completely omit the concentration of optionally biostatic or biocidal, in particular antimicrobial substances compared with the prior art and consequently to minimize the toxicological risk or the associated side effects to reach.
  • no pathogens can enter the wound from the outside, because the activated carbon layer is impassable for them.
  • the wound dressing additionally contains analgesic or analgesic agents.
  • analgesic or analgesic agents may be anti-inflammatory substances, such. As ibuprofen and diclofenac, as well as painkillers such. As lidocaine and procaine act.
  • the wound dressing contains a hemostatic agent (hemostyptic).
  • hemostyptic hemostyptic
  • One or more specific local and systemic haemostatic agents are possible.
  • hydrophilic, high molecular weight polymers such as.
  • B. Cellulosederivaten that promote hemostasis by contact activation of the endogenous coagulation system.
  • these agents allow for wound bed adaptation and at the same time function as adhesives, which in turn favors the adhesion of the wound dressing.
  • the abovementioned active substances can themselves form an independent layer but can also be integrated or incorporated into one or more layers of the wound dressing.
  • the structure of the wound dressing, the particular active ingredient concentrations and particle sizes used as well as the type of binding of the active substances in the individual layers influence their solubility behavior. A targeted delivery of time to different phases of wound healing is possible accordingly.
  • the fixation of the wound dressing in the state of use is reinforced by an adhesive edge.
  • This is in particular an adhesive surface which z. B. on the textile surface materials between which the activated carbon arranged or can be fixed and which, so to speak, form a kind of "activated carbon cushion".
  • the adhesive surface extends beyond the edges of the "activated carbon pad” and provides an adhesive border so that the wound dressing can be stably fixed to the patient's skin in this manner. It is also possible according to the invention to integrate in this area a barrier or laundry protection layer.
  • an adhesive in the present invention in a wound dressing according to the invention in particular substances such. As polyacrylate, siloxane or polyisobutadiene used.
  • an adhesive layer can be dispensed with the use of a secondary dressing or a film adhesive.
  • a lateral seal is ensured.
  • neither the wound nor the surrounding skin are irritated when using a previously described adhesive edge or adhesive layer.
  • the port edge minimizes the risk of misuse.
  • the hydrocolloid-containing, in particular collagen-containing layer is obtainable in particular by applying a dispersion or solution of a collagen on a suitable support with subsequent drying, in particular freeze-drying, preferably with expansion of the collagen, so that in this way a hydrocolloid fleece or a hydrocolloid foam, in particular, a collagen fleece or collagen foam is produced.
  • the layer containing at least one hydrocolloid, preferably collagen, a hydrocolloid or collagen suspension preferably with a hydrocolloid or collagen concentration in the range of 0.1 to 5 Wt .-%, in particular in the range of 0.5 to 4 wt .-%, preferably in the range of 0.7 to 3 wt .-%, particularly preferably in the range of 1 to 2 wt .-%, based on the hydrocolloid - or collagen suspension to produce.
  • the preferred solvent for the hydrocolloid, in particular collagen is ultrapure water and the pH of the suspension is preferably adjusted to the range from 2.5 to 5, in particular to a range from 3 to 4.
  • a disinfectant and / or antimicrobial and / or hemostatic and / or wound healing promoting and / or anti-inflammatory agent (as defined above) is introduced into the hydrocolloid or collagen suspension.
  • the amount of active substance added is variable; In this regard, reference may be made to the above statements.
  • the hydrocolloid or collagen suspension may be applied to a carrier, the thickness of the resulting, at least substantially dry hydrocolloid or collagen-containing layer being modified by the application height of the hydrocolloid or collagen suspension on the carrier can.
  • the drying is preferably carried out on the carrier, in particular by lyophilization (freeze-drying).
  • the at least substantially dry hydrocolloid or collagen layer can subsequently be removed from the carrier material (alternatively, however, only after production of the overall composite).
  • An activated carbon-containing layer can subsequently be applied to the hydrocolloid or collagen layer produced in this way, with the application being able to take place directly or indirectly.
  • at least one textile layer can be provided between the hydrocolloid or collagen layer and the actual activated carbon layer, as described below. 59
  • the activated carbon of the activated carbon-containing layer of the wound dressing according to the invention is concerned, it is preferred according to the invention if it is arranged on a flat, preferably textile support, preferably attached thereto.
  • the activated carbon of the activated carbon-containing layer is arranged between a first textile sheet material and a second textile sheet material.
  • the activated carbon of the activated carbon-containing layer is attached to the first textile sheet material and / or to the second textile sheet material, in particular by means of a preferably medically and / or physiologically compatible adhesive.
  • the activated carbon of the activated carbon-containing layer is provided with a wound-healing-promoting and / or hemostatic and / or antimicrobial and / or anti-inflammatory and / or disinfecting active ingredient.
  • the activated carbon is impregnated with the active ingredient or a drug solution.
  • the abovementioned layers namely in particular the activated carbon layer, the layer containing a hydrocolloid, preferably collagen, and the textile surface materials to be combined as a composite.
  • This can be done, in particular, by providing the layers with an outer covering layer.
  • the outer covering layer protrudes beyond the composite or the layers in its surface, wherein the protruding sections are designed, so to speak, as an adhesive edge.
  • the wound dressing is equipped with at least one adhesive, barrier and / or laundry protection layer.
  • a multilayer composite of outer hydrocolloid layer / textile surface material / activated carbon layer / textile sheet material with the above-mentioned sequence of the individual layers results.
  • Another object of the present invention is - according to a time aspect of the present invention - the use of a wound dressing according to any one of the preceding claims for therapeutic, especially topical wound care of the human or animal body, in particular for the therapeutic, preferably topical treatment of wounds and / or Gewebsunterbrechungen.
  • wounds are understood in the context of the present invention, as they are listed in particular in the introductory part.
  • a mechanical wound is understood to mean in particular puncture, cut, pinch, square, scoring or abrasion wounds.
  • the class of thermal wounds includes, in particular, tissue disruptions which are triggered by the action of extreme cold or heat.
  • chemical wounds are understood to mean those wounds which are triggered by the action of chemical substances, in particular chemical burns by alkalis or acids.
  • Radiation-induced wounds are caused, in particular, by the action of actinic or ionizing radiation.
  • the wound may be in physiological conditions which place particularly high demands on the treatment or therapy. So it comes in necrotizing wounds to dissolve the cell structure or to the death of tissue.
  • wounds are infected by pathogens such as bacteria, fungi or viruses.
  • pathogens such as bacteria, fungi or viruses.
  • a wound which has not healed completely after a period of approximately eight weeks is defined as a chronic wound.
  • a chronic wound Under a chronic wound z.
  • pressure ulcers as often seen in bedridden patients. occur on the other hand wounds, as they often associated with circulatory disorders, z.
  • the wound dressing according to the invention for the therapeutic treatment of mechanical wounds, in particular cuts, punctures, pinching, square, scoring and / or abrasions.
  • wound dressing according to the invention for the therapeutic treatment of thermal wounds, in particular wounds caused by cold or heat-burning.
  • the wound dressing according to the invention for the therapeutic treatment of chemical wounds, in particular by means of burns caused by alkalis and / or acids.
  • the wound dressing for the therapeutic treatment of necrotizing and / or infected and / or chronic wounds.
  • the wound dressing according to the invention for the therapeutic treatment of acute wounds.
  • the wound dressing according to the invention for the therapeutic treatment of pressure ulcers and / or wounds caused by circulatory disorders.
  • wound dressings according to the invention had the following features:
  • the wound dressings A and A 'each had a collagen layer and an activated carbon layer arranged between two textile surface materials based on polyamide;
  • the wound dressings B and B * also each had a collagen layer and an activated charcoal layer arranged between two textile support materials based on polyamide and, moreover, both the collagen layer and the activated carbon layer were provided with octenidine.
  • the wound dressing C also had a collagen layer and an activated charcoal layer arranged between two polyamide-based textile substrates and, moreover, both the collagen layer and the activated carbon layer were provided with polyhexanide.
  • the other wound dressings had the following properties:
  • Wound pad D was based on a standard activated carbon nonwoven
  • Wound Dressing F was based exclusively on collagen foam.
  • the collagen layer of the wound dressings was in each case produced starting from an aqueous collagen suspension with subsequent lyophilization on a suitable support, resulting in a corresponding collagen foam.
  • Collagen based on porcine skin was used.
  • Activated carbon for wound dressings A, B, and C was in each case a spherical activated carbon from Adsor-Tech GmbH, Premnitz / Federal Republic of Germany, the activated carbon being obtained by carbonation and subsequent activation of organic polymers based on polystyrene, in particular divinyl-crosslinked polystyrene. 0.2 to 0.6 mm, microporous fraction: about 76%, BET surface area: about 1.775 m Ig, total pore volume according to Gurvich: about 2.2 m 2 / g; / Bursting strength:> 15 Newton / Activated Carbon Sphere; fractal dimension of open porosity: 2.55; Abrasion resistance: 100%).
  • the activated carbon used for the wound dressings A 'and B' was in each case a commercially available spherical activated carbon based on phenolic resin (absolute particle size: about 0.2 to 0.6 mm, microporous fraction: about 57%, BET surface area: about 1.375 g 2 / g; total pore volume according to Gurvich: about 1.5 m 2 / g; compressive / bursting strength: ⁇ 10 newton / activated carbon ball; fractal dimension of open porosity: 2.15; abrasion resistance: 87%).
  • the inhibitor test was carried out as part of a modified according to Bauer Kirby (DIN 58940-3) test.
  • the test examined the extent to which wound dressings are capable of inhibiting the growth of the hospital germs Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Proteus mirabilis on solid media.
  • the area [mm] of the zone of inhibition around the wound dressing - d. H. the area in which no bacterial growth took place was measured and evaluated as a measure of the antimicrobial effectiveness of the respective wound dressing.
  • the inhibitor test was carried out on solid media based on blood agar with 5% by weight sheep blood. Before inoculating the solid medium, dilutions of the test germs were prepared in such a way that countable colony-forming units were formed on the blood plates. The respective dilutions of the test microbial suspension were plated under sterile conditions. Subsequently, the wound dressings were cut aseptically into 1 cm x 1 cm pieces with a scalpel, placed on the culture plates under sterile conditions and removed again after 24 hours lay-up time. This was followed by aerobic cultivation at 37 ° C. The area of the inhibition zones around the respective wound dressings was measured digitally after a total of 48 hours of incubation. The evaluation was then carried out by comparing the inhibition zones formed around the respective wound dressing.
  • the hospital germs Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa and Proteus mirabilis were able to be inhibited in an outstanding manner in their growth with all the wound dressings according to the invention.
  • the strongest growth inhibition was achieved using the wound dressing C according to the invention, which additionally had polyhexanide as the antimicrobial active ingredient.
  • wound dressings A and A ' which were based on a combination of collagen foam and activated carbon, the growth of the microorganisms listed above could be satisfactorily inhibited during the inhibitor test, but less efficiently than with the wound dressings B, B' and C.
  • the comparative study papers D, E and F did not show such an efficient or satisfactory inhibition of the growth of the aforementioned germs.
  • the comparison of the wound dressings A and B according to the invention with the wound dressings A 'and B' according to the invention shows, in particular, polystyrene-based activated carbons having a high microporosity, a large BET surface area and a large fractal Dimension of the open porosity, as sold in particular by Adsor-Tech GmbH, have particularly good antimicrobial properties.
  • wound dressings according to the invention is, in particular, also to be seen in the fact that their use can also inhibit the growth of those microorganisms which are known for the increased occurrence of antibiotic resistances, in particular the so-called hospital germs.
  • wound dressing A the wounds in 9 subjects of the first group (wound dressing A) and after 3 weeks of therapy in 13 subjects of the second group (wound dressing B) were completely closed and largely epithelized. In the other subjects, the wounds were partially not completely closed, however, the wound base appeared rosy and granulating and the wound environment was intact, which suggests an early healing of the wound. On the basis of the evaluation of the condition of the wounds after three or four weeks, a satisfactory overall result with regard to the healing progress in chronic wounds was recorded. With regard to the effectiveness of Wound Dressings A and B, additional dressing of the wound dressing with an antimicrobial agent, such as octenidine, accelerates wound healing. In particular, in the subjects treated with wound dressing B, a faster decline of inflammatory symptoms, in particular in the presence of infections, could be observed.
  • an antimicrobial agent such as octenidine
  • wound dressing E With the wound dressing E, no results comparable with the wound dressings A and B could likewise be achieved. Only 2 of the 15 subjects treated with wound dressing E had the wound completely closed or epithelized. In a total of 8 of the 15 volunteers, the wound surface appeared rosy and granulating, suggesting a progression of the healing process. In 2 subjects, the wound base was still fibrin-occupied, which is a characteristic of the early stages of the healing process. In addition, 2 of the 15 volunteers had infected the wound, so that sometimes severe inflammatory symptoms occurred. Wound pads based on polyurethane foam, which was impregnated with a disinfectant, provide overall neither optimal protection against contamination nor satisfactory odor adsorption.
  • the relevant results for the wound dressings tested are shown in Table 2 below:
  • the applied and efficacy observations show the excellent efficacy of wound dressings A and B in the treatment of chronic wounds, especially in connection with pressure sores and wounds associated with underlying disorders associated with circulatory disorders.
  • the wound dressings according to the invention are improved in many respects over non-inventive wound dressings - in particular by the biostatic or biocidal equipment or properties and / or by the combination of activated carbon on the one hand and collagen on the other hand.
  • the wound dressings according to the invention when using the wound dressings according to the invention for therapeutic wound care, the healing process of the wound is significantly accelerated.
  • the wound dressings according to the invention have good odor adsorption properties, which, above all, benefits the well-being of the patients.

Abstract

L'invention concerne un pansement qui est adapté en particulier au traitement thérapeutique des plaies, ledit pansement présentant une structure multicouche, laquelle comprend d'une part au moins une couche contenant un hydrocolloïde, de préférence du collagène, ("couche d'hydrocolloïde ou de collagène"), et d'autre part au moins une couche contenant du charbon actif ("couche de charbon actif").
EP20120756104 2011-09-02 2012-08-31 Pansement multicouche contenant un hydrocolloïde et du charbon actif Active EP2736542B1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PL12756104T PL2736542T3 (pl) 2011-09-02 2012-08-31 Wielowarstwowy opatrunek na ranę zawierający hydrokoloid i węgiel aktywny

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102011112102 2011-09-02
DE102011120491A DE102011120491A1 (de) 2011-09-02 2011-12-08 Wundauflage
PCT/EP2012/003659 WO2013029796A1 (fr) 2011-09-02 2012-08-31 Pansement multicouche contenant un hydrocolloïde et du charbon actif

Publications (2)

Publication Number Publication Date
EP2736542A1 true EP2736542A1 (fr) 2014-06-04
EP2736542B1 EP2736542B1 (fr) 2015-05-06

Family

ID=46967641

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20120756104 Active EP2736542B1 (fr) 2011-09-02 2012-08-31 Pansement multicouche contenant un hydrocolloïde et du charbon actif

Country Status (10)

Country Link
US (1) US9782512B2 (fr)
EP (1) EP2736542B1 (fr)
JP (1) JP5827408B2 (fr)
CN (1) CN103889468B (fr)
CA (1) CA2846682C (fr)
DE (2) DE102011120491A1 (fr)
ES (1) ES2544106T3 (fr)
IL (1) IL231189A (fr)
PL (1) PL2736542T3 (fr)
WO (1) WO2013029796A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804654D0 (en) 2008-03-13 2008-04-16 Smith & Nephew Vacuum closure device
US9421132B2 (en) 2011-02-04 2016-08-23 University Of Massachusetts Negative pressure wound closure device
CN106974683B (zh) 2011-02-04 2020-02-21 马萨诸塞州大学 负压伤口闭合装置
EP2852333B1 (fr) 2012-05-22 2021-12-15 Smith & Nephew plc Appareils pour une thérapie de plaie
WO2014013348A2 (fr) 2012-05-22 2014-01-23 Smith & Nephew Plc Dispositif de fermeture de blessure
EP3470029A1 (fr) 2012-05-24 2019-04-17 Smith & Nephew, Inc. Dispositifs de traitement et de fermeture de plaies par pression négative
US9962295B2 (en) 2012-07-16 2018-05-08 Smith & Nephew, Inc. Negative pressure wound closure device
JP6407954B2 (ja) 2013-03-13 2018-10-17 スミス アンド ネフュー インコーポレイテッド 陰圧創傷閉鎖デバイスおよびシステムならびに陰圧による創傷治療での使用方法
RU2015142877A (ru) 2013-03-14 2017-04-18 СМИТ ЭНД НЕФЬЮ ПиЭлСи Сжимаемые наполнители раны и системы и способы их применения в лечении ран с применением отрицательного давления
US20150005391A1 (en) 2013-06-26 2015-01-01 COLE Research & Design, Inc. Method of reducing scarring
RU2016104132A (ru) 2013-07-16 2017-08-21 СМИТ ЭНД НЕФЬЮ ПиЭлСи Устройство для лечения ран
MY184693A (en) * 2013-08-22 2021-04-17 Univ Kebangsaan Malaysia Ukm Bilayer hydrocolloid films containing therapeutic agents
CN103394117B (zh) * 2013-08-28 2014-09-03 广东泰宝医疗科技股份有限公司 一种自粘型复合活性炭纤维敷料及其制备方法
CN106170275B (zh) 2013-10-21 2021-05-07 史密夫和内修有限公司 负压伤口闭合装置
US10201642B2 (en) 2014-01-21 2019-02-12 Smith & Nephew Plc Collapsible dressing for negative pressure wound treatment
US10179073B2 (en) 2014-01-21 2019-01-15 Smith & Nephew Plc Wound treatment apparatuses
KR101575178B1 (ko) * 2014-06-10 2015-12-07 (주)시지바이오 차콜 드레싱재 및 그의 제조 방법
WO2016057831A1 (fr) * 2014-10-10 2016-04-14 COLE Research & Design, Inc. Procédé de réduction de la formation de cicatrices
AU2016254119A1 (en) 2015-04-29 2017-10-05 Smith & Nephew Inc. Negative pressure wound closure device
CZ28634U1 (cs) 2015-05-05 2015-09-14 Contipro Pharma A.S. Dentální přípravek na bázi hyaluronanu a oktenidin dihydrochloridu
US11471586B2 (en) 2015-12-15 2022-10-18 University Of Massachusetts Negative pressure wound closure devices and methods
FR3053892A1 (fr) * 2016-07-12 2018-01-19 Urgo Recherche Innovation Et Developpement Pansement permettant la liberation controlee et prolongee de la metformine
US11135351B2 (en) 2016-08-30 2021-10-05 Smith & Nephew Plc Systems and methods for applying reduced pressure therapy
CN106237371A (zh) * 2016-09-21 2016-12-21 振德医疗用品股份有限公司 双层复合止血海绵、制作双层复合止血海绵的模具及方法
US11096832B2 (en) 2016-09-27 2021-08-24 Smith & Nephew Plc Wound closure devices with dissolvable portions
EP3534856A1 (fr) 2016-11-02 2019-09-11 Smith & Nephew, Inc Dispositifs de fermeture de plaie
EP3338813B1 (fr) * 2016-12-20 2020-01-29 BSN Medical GmbH Produit de traitement de plaie multicouche ayant une couche de libération perforée
JP2020523056A (ja) 2017-06-07 2020-08-06 ケーシーアイ ユーエスエイ, インコーポレイテッドKci Usa, Inc. 臭気吸収性及び増加された水蒸気透過性を有する創傷被覆材
US11324876B2 (en) 2017-06-13 2022-05-10 Smith & Nephew Plc Collapsible structure and method of use
AU2018285236B2 (en) 2017-06-13 2024-02-29 Smith & Nephew Plc Wound closure device and method of use
US11395873B2 (en) 2017-06-14 2022-07-26 Smith & Nephew, Inc. Control of wound closure and fluid removal management in wound therapy
EP3638170B1 (fr) 2017-06-14 2024-03-13 Smith & Nephew PLC Structure pliable pour fermeture de plaie et méthode d'utilisation
EP3638332A1 (fr) 2017-06-14 2020-04-22 Smith & Nephew, Inc Gestion de l'élimination de liquide et maîtrise de la fermeture d'une plaie dans un traitement de plaie
EP3638174A1 (fr) 2017-06-14 2020-04-22 Smith & Nephew plc Feuille pliable pour fermeture de plaie et procédé d'utilisation
WO2019020544A1 (fr) 2017-07-27 2019-01-31 Smith & Nephew Plc Dispositif de fermeture de plaie personnalisable et son procédé d'utilisation
US11712373B2 (en) * 2017-07-29 2023-08-01 Edward D. Lin Wound therapy apparatus with scar modulation properties and related methods
WO2019030136A1 (fr) 2017-08-07 2019-02-14 Smith & Nephew Plc Dispositif de fermeture de plaie doté d'une couche protectrice et procédé d'utilisation
WO2019042790A1 (fr) 2017-08-29 2019-03-07 Smith & Nephew Plc Systèmes et procédés pour surveiller la fermeture d'une plaie
JP2019107284A (ja) * 2017-12-19 2019-07-04 株式会社大木工藝 装身具
WO2020043665A1 (fr) * 2018-08-27 2020-03-05 Claudia Eder Gel antiseptique
RU2709462C1 (ru) * 2019-03-15 2019-12-18 Наталья Васильевна Меньшутина Ранозаживляющее и гемостатическое средство на основе хитозана и способ его получения
CN110624127A (zh) * 2019-10-14 2019-12-31 河南承东生物科技有限公司 一种双重抑菌促愈合液体敷料及其制备方法
CN112683014B (zh) * 2020-12-24 2022-07-08 杭州协合医疗用品有限公司 一种淀粉止血微球中有机溶剂的脱除方法

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065372D1 (en) * 1979-09-07 1983-11-24 Kingsdown Medical Consultants Wound dressing
NZ203706A (en) * 1982-04-22 1986-03-14 Squibb & Sons Inc Occlusive multi-layer wound dressing and hydrocolloidal granules for wound treatment
EP0227955A3 (fr) * 1982-07-21 1987-11-25 University of Strathclyde Pansement composite pour blessures
GB8723447D0 (en) 1987-10-06 1987-11-11 Johnson & Johnson Ltd Wound dressing
JPH0790147B2 (ja) 1990-01-08 1995-10-04 株式会社フジタ フィルター交換時期判別装置
GB9413931D0 (en) * 1994-07-11 1994-08-31 C V Lab Ltd Alginate fabric, method of preparation and use
US5985008A (en) * 1997-05-20 1999-11-16 Advanced Technology Materials, Inc. Sorbent-based fluid storage and dispensing system with high efficiency sorbent medium
US6124521A (en) * 1999-03-10 2000-09-26 Tri-State Hospital Supply Corporation Dermal wound window dressing securement system
US6867287B2 (en) * 2000-04-25 2005-03-15 The Procter & Gamble Company Breathable absorbent articles comprising chitosan material
JP2001333973A (ja) * 2000-05-26 2001-12-04 Unitika Ltd 抗菌性活性炭シート及び抗菌性脱臭創傷被覆材
US20020168400A1 (en) * 2001-05-11 2002-11-14 Biocore Medical Technologies, Inc. Collagen/synthetic resin foam wound dressing
GB2376632B (en) * 2001-06-21 2004-10-27 Johnson & Johnson Medical Ltd Removable cavity wound dressing
DE20221998U1 (de) 2002-11-20 2010-05-12 BLüCHER GMBH Kugelaktivkohle
GB2405343A (en) * 2003-08-29 2005-03-02 Johnson & Johnson Medical Ltd Charcoal Wound Dressings
JP5383976B2 (ja) * 2003-09-08 2014-01-08 エフエムシー バイオポリマー エイエス ゲル化バイオ重合体基材発泡体
CN1720801A (zh) * 2004-07-12 2006-01-18 深圳市清华源兴生物医药科技有限公司 一种载银杀菌活性炭及其制备方法与应用
US7371270B2 (en) 2004-11-24 2008-05-13 Welland Medical Limited Odour absorbing filters
JP5208752B2 (ja) * 2005-10-18 2013-06-12 オーガノジェネシス・インコーポレイテッド 抗菌性コラーゲン構築物
DE202006016821U1 (de) * 2005-11-02 2007-03-29 Riesinger, Birgit Absorbierender Körper zur Anbringung an menschliche oder tierische Körperoberflächen
EP2359784B1 (fr) 2005-11-02 2017-09-27 BSN medical GmbH Corps d'absorption destiné à être appliqué sur la surface cutanée d'un être humain ou d'un animal
US7517536B2 (en) 2005-11-25 2009-04-14 Feng Chia University Antimicrobial compositions and wound dressings
TWI354549B (en) 2005-11-25 2011-12-21 Univ Feng Chia Antimicrobial compositions and wound dressings
DE102007009672B4 (de) 2006-04-07 2014-02-20 Preh Gmbh Klimabedienteil mit einer Sensoranordnung
DE102007030931A1 (de) 2007-07-03 2009-01-08 Birgit Riesinger Zusammensetzung, enthaltend mindestens einen nutritiven, mindestens einen desinfizierenden bzw. dekontaminierenden und/oder mindestens einen Proteasen hemmend wirkenden Wirkstoff und/oder Wirkstoffkomplex
EP2072063A1 (fr) * 2007-12-22 2009-06-24 Bayer Innovation GmbH Mousse de polyuréthane à base de pré-polymère hydrophile cellulaire résistante aux infections, procédé pour sa fabrication et son utilisation dans des pansements antiseptiques
DE102009053305A1 (de) 2009-11-12 2011-08-18 medichema GmbH, 09112 Verfahren zur Herstellung einer schichtförmigen Wundauflage

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2013029796A1 *

Also Published As

Publication number Publication date
PL2736542T3 (pl) 2015-10-30
DE202011108805U1 (de) 2012-09-03
CA2846682A1 (fr) 2013-03-07
US9782512B2 (en) 2017-10-10
CN103889468B (zh) 2018-06-29
IL231189A0 (en) 2014-04-30
IL231189A (en) 2017-10-31
CA2846682C (fr) 2016-03-29
US20150157758A1 (en) 2015-06-11
JP2014529449A (ja) 2014-11-13
EP2736542B1 (fr) 2015-05-06
WO2013029796A1 (fr) 2013-03-07
DE102011120491A1 (de) 2013-03-07
ES2544106T3 (es) 2015-08-27
CN103889468A (zh) 2014-06-25
JP5827408B2 (ja) 2015-12-02

Similar Documents

Publication Publication Date Title
EP2736542B1 (fr) Pansement multicouche contenant un hydrocolloïde et du charbon actif
EP2734244B1 (fr) Pansement pour plaie comprenant une couche permeable a l'air
EP2734245B1 (fr) Pansement pour plaies ayant une activite antimicrobienne
Sarheed et al. Antimicrobial dressings for improving wound healing
WO2019089856A1 (fr) Pansement absorbant, perméable à l'air, bloquant/tuant les agents pathogènes et fabrication associée
EP2747792A1 (fr) Article d'hygiène ou de soin comportant une certaine proportion de cuivre ou d'ions cuivre
KR101366417B1 (ko) 천연물질을 이용한 항균성 창상 피복재 및 그 제조방법
EP2683418A1 (fr) Produits permettant la liaison de toxines bactériennes et leur élimination lors du traitement d'infections locales, et leur préparation
Elsner et al. Novel composite antibiotic-eluting structures for wound healing applications

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20150227

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 725248

Country of ref document: AT

Kind code of ref document: T

Effective date: 20150615

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502012003100

Country of ref document: DE

Effective date: 20150618

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 4

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2544106

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20150827

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20150506

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150907

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150806

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: PL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150906

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150806

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150807

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502012003100

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: RO

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150506

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150831

26N No opposition filed

Effective date: 20160209

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 5

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120831

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150831

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20211025

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 20220825

Year of fee payment: 11

Ref country code: GB

Payment date: 20220822

Year of fee payment: 11

Ref country code: DE

Payment date: 20220826

Year of fee payment: 11

Ref country code: AT

Payment date: 20220822

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20220824

Year of fee payment: 11

Ref country code: FR

Payment date: 20220823

Year of fee payment: 11

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20220824

Year of fee payment: 11

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20231004

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220901

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 502012003100

Country of ref document: DE

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MM01

Ref document number: 725248

Country of ref document: AT

Kind code of ref document: T

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230831